Dexamethasone reduces infusion-related reactions in patients with EGFR-mutated NSCLC treated with intravenous Rybrevant

Flatiron Health surpasses 1,000 research publications using RWD from its de-identified patient database

Flatiron Health announced a milestone of over 1,000 research publications utilizing Flatiron’s electronic health record-derived real world data.

October 18, 2024

Vol.50 No.39

Cancer History Project Conversation with The Cancer Letter

Tom Lynch reflects on discovery of the EGFR mutations’ role in lung cancer

On Nov. 24, 2003, an article in The Boston Globe told the story of a patient’s remarkable response to gefitinib, a drug that had recently been approved by FDA.

October 04, 2024

Vol.50 No.37

By Paul Goldberg and McKenzie Prillaman

Drugs & Targets

FDA approves Tagrisso for stage 3 EGFR-mutated NSCLC

FDA approved Tagrisso (osimertinib) in the U.S. for treatment of adult patients with unresectable, stage 3 epidermal growth factor receptor-mutated non-small cell lung cancer whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy.

September 27, 2024

Vol.50 No.36

Clinical Roundup

Rybrevant + chemo shows improved OS data in NSCLC

Updated results from the phase III MARIPOSA-2 study showed Rybrevant (amivantamab-vmjw) combined with chemotherapy led to consistent benefit across post-progression outcomes in adult patients with previously treated NSCLC with epidermal growth factor receptor exon 19 deletions or L858R substitution mutations.

September 20, 2024

Vol.50 No.35

Drugs & Targets

FDA approves Rybrevant + pemetrexed + chemo in NSCLC with EGFR exon 19 deletions or L858R mutations

FDA approved Rybrevant (amivantamab-vmjw) with carboplatin and pemetrexed for adult patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 L858R substitution mutations whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor.

September 20, 2024

Vol.50 No.35

Clinical Roundup

Friends publishes evaluation of RWE in NSCLC

Findings by Friends of Cancer Research were published recently in JCO Clinical Cancer Informatics in a paper titled “Evaluation of real-world tumor response derived from electronic health record data sources: A feasibility analysis in mNSCLC patients treated with chemotherapy.”

September 13, 2024

Vol.50 No.34

Dexamethasone reduces infusion-related reactions in patients with EGFR-mutated NSCLC treated with intravenous Rybrevant

YOU MAY BE INTERESTED IN

Flatiron Health surpasses 1,000 research publications using RWD from its de-identified patient database

Tom Lynch reflects on discovery of the EGFR mutations’ role in lung cancer

FDA approves Tagrisso for stage 3 EGFR-mutated NSCLC

Rybrevant + chemo shows improved OS data in NSCLC

FDA approves Rybrevant + pemetrexed + chemo in NSCLC with EGFR exon 19 deletions or L858R mutations

Friends publishes evaluation of RWE in NSCLC

Renew today!

Subscriber content

Never miss an issue!

Login